.svg){kind=small}
Back
NEW YORK, November 25, 2025 — Tema ETFs (“Tema”), the New York-based provider of innovative exchange-traded funds (ETFs), is pleased to announce the Tema Oncology ETF (“CANC”) has surpassed $100m in assets under management (AUM) two years since launch. The CANC ETF invests in oncology companies and cancer therapies and is the only pure-play oncology focused ETF in the world, managed by Dr David Song MD, PhD, CFA. 1
Three Highlights of the Tema Oncology ETF (CANC):
1. The Oncology Need
Cancer is the number one leading cause of death under the age of 85 according to a January 2025 study published by the American Cancer Society, with a notable rise in prevalence amongst women and younger men. In some countries, like the UK, the lifetime risk of cancer is now more than 50% in people born since 1960 according to the British Medical Journal (BMJ).1
The total universe of publicly traded, oncology-focused companies exceeds 150 companies globally, yet only a subset of these companies are deemed investible, and require deep expertise and risk management to identify.
2. 2025 Performance
The Tema Oncology ETF is up +43.7% in 2025 year-to-date compared to +14.1% for the S&P 500 index and +20.1% for the S&P Biotechnology Select XBI Index*.
Based on Bloomberg’s defined universe of 47 healthcare and biotechnology ETFs, the Tema Oncology ETF is the third best performing healthcare and biotechnology ETF 2025 year-to-date.2
3. Healthcare Expertise
Dr David Song MD, PhD originally qualified as a doctor, with an MD degree at the University of Pennsylvania, followed by a ~25-year healthcare investment track record at firms including Rockefeller Capital, Balyasny and Millennium.
Outside his investment activities, Dr Song volunteers his time mentoring graduate students and entrepreneurial-minded scientists at academic institutions like Scripps Research, a leading biomedical research institute in California, through which Dr Song is exposed to breakthrough biomedical innovations including in oncology.
“Biomedical investing has been my passion and mission since I graduated from the University of Pennsylvania as a qualified doctor over 25 years ago. Cancer remains one of the deadliest and most disruptive diseases in the world and through CANC I hope to offer investors an opportunity to invest in the fight against cancer and support breakthrough medical innovations improving patient outcomes and lives.” said Dr David Song, Portfolio Manager for the Tema Oncology ETF.
About Tema ETFs
Tema ETFs is an active ETF investment manager founded in 2023 to empower investors with durable and strategic portfolio solutions spanning quality, core, thematics and alternatives. Tema is backed by Index Ventures, Accel Partners and over a dozen financials services CEOs and FinTech founders.
Disclosures
Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com. Read the prospectus carefully before investing.
Investing involves risk including possible loss of principal. There is no guarantee the adviser’s investment strategy will be successful.
Industry Concentration Risk: Because the Fund's assets will be concentrated in an industry or group of industries, the Fund is subject to loss due to adverse occurrences that may affect that industry or group of industries.
Biotechnology Industry Risk: The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits. In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized and more volatile than companies with greater capitalizations.
Oncology Companies Risk: Oncology companies are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company's valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable.
The stock prices of oncology companies have been and will likely continue to be very volatile. The costs associated with developing new drugs can be significant, and the results are unpredictable. Newly developed drugs may be susceptible to product obsolescence due to intense competition from new products and less costly generic products. Moreover, the process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained.
An investment cannot be made directly into an index.
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. For performance data current to the most recent month-end, visit https://temaetfs.com/canc.
